SCHEMBL7609293

SCHEMBL7609293

CCCCCCCCSCc1cccc(CC)c1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.55
GABRB2 P47870 1/20 0.55
TYR P14679 1/20 0.41
BID P55957 3/20 0.41
MCL1 Q07820 3/20 0.41
BCL2L1 Q07817 2/20 0.41
BAK1 Q16611 2/20 0.41
KAT8 Q9H7Z6 2/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
EP300 Q09472 1/20 0.41
KAT2A Q92830 1/20 0.41
KAT2B Q92831 1/20 0.41
KAT5 Q92993 1/20 0.41
SAE1 Q9UBE0 1/20 0.41
CES2 O00748 3/20 0.40
ALOX5 P09917 1/20 0.40
PTGS2 P35354 1/20 0.40
GMNN O75496 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27808100 0.93 GABRA1 (0.59) GABRA1GABRB2TYRBIDMCL1
SCHEMBL27839580 0.86 EGFR (0.40) TYRBIDMCL1BCL2L1BAK1
SCHEMBL2554415 0.86 EGFR (0.40) TYRBIDMCL1BCL2L1BAK1
SCHEMBL227298 0.86 EGFR (0.40) TYRBIDMCL1BCL2L1BAK1
SCHEMBL30865024 0.86 EGFR (0.40) TYRBIDMCL1BCL2L1BAK1
SCHEMBL7185371 0.85 CA2 (0.44) GABRA1GABRB2TYRBIDMCL1
SCHEMBL3928826 0.85 GABRA1 (0.49) GABRA1GABRB2TYRBCL2L1MAPT
SCHEMBL27839575 0.84 EGFR (0.41) GABRA1GABRB2TYRALOX5PTGS2
SCHEMBL5705199 0.83 GABRA1 (0.37) GABRA1GABRB2TYRBIDMCL1
SCHEMBL6075251 0.81 LIPG (0.44) TYRCES2GMNNTP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117413025-A Phosphite compositions 住友化学株式会社 2024-01-16 CN disclosed
US-10683455-B2 Macromolecular antioxidants based on dual type moiety per molecule: structures, methods of making and using the same POLNOX CORPORATION (US) 2020-06-16 US disclosed
US-20190292454-A1 Macromolecular Antioxidants Based On Dual Type Moiety Per Molecule: Structures, Methods Of Making And Using The Same POLNOX CORPORATION 2019-09-26 US disclosed
EP-1263856-A1 STABILIZER COMPOSITION BASF AKTIENGESELLSCHAFT (DE) 2002-12-11 EP disclosed
WO-2001057122-A1 STABILIZER COMPOSITION BASF AKTIENGESELLSCHAFT (DE) 2001-08-09 WO disclosed
CN-1132763-A Low-dust granules of plastic additives CIBA GEIGY AG (CH) 1996-10-09 CN disclosed
CN-1114662-A Stabilized flexible PVC CIBA GEIGY AG (CH) 1996-01-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683455-B2 Macromolecular antioxidants based on dual type moiety per molecule: structures, methods of making and using the same LPO, GPX4, DUOX2 GABRA1 3701/4885GABRB2 3047/4885TYR 532/4885
US-20190292454-A1 Macromolecular Antioxidants Based On Dual Type Moiety Per Molecule: Structures, Methods Of Making And Using The Same LPO, GPX4, DUOX2 GABRA1 3701/4885GABRB2 3047/4885TYR 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.